Hcw Biologics Stock Performance
| HCWB Stock | USD 0.30 0.01 3.23% |
On a scale of 0 to 100, HCW Biologics holds a performance score of 1. The firm retains a Market Volatility (i.e., Beta) of -0.63, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning HCW Biologics are expected to decrease at a much lower rate. During the bear market, HCW Biologics is likely to outperform the market. Please check HCW Biologics' potential upside and the relationship between the skewness and period momentum indicator , to make a quick decision on whether HCW Biologics' current trending patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in HCW Biologics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, HCW Biologics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | HCW Biologics Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco o... | 01/15/2025 |
2 | HCW Biologics Insiders Placed Bullish Bets Worth US2.50m | 01/23/2025 |
3 | HCW Biologics Shows Market Volatility Amid Clinical Trial | 01/30/2025 |
4 | Whats Going On With HCW Biologics Stock Monday | 02/03/2025 |
5 | Acquisition by Byam Rebecca of 20000 shares of HCW Biologics at 1.6598 subject to Rule 16b-3 | 02/19/2025 |
6 | HCW Biologics Inc. announced that it expects to receive 20 million in funding -February 19, 2025 - Marketscreener.com | 02/24/2025 |
7 | Acquisition by Giles Lisa M. of 41841 shares of HCW Biologics at 2. subject to Rule 16b-3 | 03/03/2025 |
8 | HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with ... | 03/06/2025 |
9 | Acquisition by Winer Gary M of tradable shares of HCW Biologics at 2.05 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 22.3 M |
HCW |
HCW Biologics Relative Risk vs. Return Landscape
If you would invest 45.00 in HCW Biologics on December 20, 2024 and sell it today you would lose (15.00) from holding HCW Biologics or give up 33.33% of portfolio value over 90 days. HCW Biologics is currently generating 0.2897% in daily expected returns and assumes 17.8312% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than HCW, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
HCW Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HCW Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as HCW Biologics, and traders can use it to determine the average amount a HCW Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0162
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HCWB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 17.83 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average HCW Biologics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HCW Biologics by adding it to a well-diversified portfolio.
HCW Biologics Fundamentals Growth
HCW Stock prices reflect investors' perceptions of the future prospects and financial health of HCW Biologics, and HCW Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HCW Stock performance.
| Return On Equity | -3.44 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (22.36) % | ||||
| Current Valuation | 25.74 M | ||||
| Shares Outstanding | 37.82 M | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 3.99 X | ||||
| Revenue | 2.84 M | ||||
| Gross Profit | 4.1 M | ||||
| EBITDA | (23.58 M) | ||||
| Net Income | (24.99 M) | ||||
| Cash And Equivalents | 32.41 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 6.3 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 30.25 X | ||||
| Book Value Per Share | (0.17) X | ||||
| Cash Flow From Operations | (22.51 M) | ||||
| Earnings Per Share | (1.05) X | ||||
| Market Capitalization | 11.95 M | ||||
| Total Asset | 28.51 M | ||||
| Retained Earnings | (70.53 M) | ||||
| Working Capital | (2.34 M) | ||||
About HCW Biologics Performance
By analyzing HCW Biologics' fundamental ratios, stakeholders can gain valuable insights into HCW Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HCW Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HCW Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 141.58 | 134.50 | |
| Return On Tangible Assets | (1.01) | (1.06) | |
| Return On Capital Employed | (1.50) | (1.42) | |
| Return On Assets | (1.01) | (1.06) | |
| Return On Equity | (2.14) | (2.03) |
Things to note about HCW Biologics performance evaluation
Checking the ongoing alerts about HCW Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HCW Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HCW Biologics had very high historical volatility over the last 90 days | |
| HCW Biologics has some characteristics of a very speculative penny stock | |
| HCW Biologics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.84 M. Net Loss for the year was (24.99 M) with profit before overhead, payroll, taxes, and interest of 4.1 M. | |
| HCW Biologics currently holds about 32.41 M in cash with (22.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 52.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with ... |
- Analyzing HCW Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HCW Biologics' stock is overvalued or undervalued compared to its peers.
- Examining HCW Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HCW Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of HCW Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HCW Biologics' stock. These opinions can provide insight into HCW Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HCW Stock analysis
When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |